Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Explore this paper's citation graph
Summary
In patients with transthyretin amyloid cardiomyopathy, tafamidis was associated with reductions in all‐cause mortality and cardiovascular‐related hospitalizations and reduced the decline in functional capacity and quality of life as compared with placebo.
- Type
- article
- Published
- 2018-08-27
- Cited by
- 2,199
- References
- 35
- Access
- Open access
- OpenAlex
- https://openalex.org/W2888036721
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205103334
Keywords
Transthyretin, Hazard ratio, Medicine, Placebo, Internal medicine
References
- Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A.
- Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
- Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein.
- Trans-Suppression of Misfolding in an Amyloid Disease
- Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure
- Transthyretin-related amyloidoses and the heart: a clinical overview
- Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.
- Combining mortality and longitudinal measures in clinical trials.
- Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.
- 99mTc-Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses
- Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure.
- An example of using mixed models and PROC MIXED for longitudinal data.
- Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs
- Effect of Cardiac Resynchronization Therapy on Reverse Remodeling and Relation to Outcome: Multicenter Automatic Defibrillator Implantation Trial: Cardiac Resynchronization Therapy
- Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
- Bone scintigraphy with 99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis
- Contemporary Reviews in Cardiovascular Medicine Transthyretin (TTR) Cardiac Amyloidosis
- Usefulness of 99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis
- Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness.
- Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
Cited by
- Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines
- Pharmacological treatment for familial amyloid polyneuropathy.
- Tafamidis: a new treatment for ATTR cardiomyopathy
- Breaking through the barrier: Finally hope for patients with cardiac amyloidosis
- Beyond NEOD001 for systemic light-chain amyloidosis.
- Case series: clinical outcomes of the transthyretin valine-to-isoleucine mutation in a brother–sister pair
- Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy
- Early Diagnosis of Cardiac Amyloidosis by Carpal Tunnel Surgery: Is it All in the Wrist?
- Analysis of the TTR gene in the investigation of amyloidosis: A 25‐year single UK center experience
- Doksycyklina w terapii amyloidozy układowej z zajęciem serca
- Nowe metody diagnostyki amyloidozy serca. Seria przypadków amyloidozy transtyretynowej
- Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy
- Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
- Discussion forum response to Canepa et al.
- State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis
- Amyloid Heart Disease
- Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
- Amyloidosis in Australia
- Two-dimensional Strain Echocardiography Differentiates Cardiac Amyloidosis from Hypertrophic Cardiomyopathy with Preserved Ejection Fraction
- Early Diagnosis of Cardiac Amyloidosis. A Step Forward
Related papers
- Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis
- Variant transthyretin in cerebrospinal fluid in familial amyloidotic polyneuropathy.
- Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, Portuguese type.
- [Transthyretin: its functions and involvement in the pathogenicity of various diseases].
- Presence of variant transthyretin in aqueous humor of a patient with familial amyloidotic polyneuropathy after liver transplantation
- Transthyretin (prealbumin) gene expression in choroid plexus is strongly conserved during evolution of vertebrates.
- Serum transthyretin levels in patients with burn injury.
- Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex.
- Transthyretin distribution in the developing choroid plexus of the South American opossum (Monodelphis domestica)